About
About Honz Pharmaceutical Co., Ltd
Honz Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pediatric medicines in China and internationally. It operates through Pharmaceutical Manufacturing and Sales; and Daily Necessities Manufacturing and Sales segments. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal, cough relief, anti-flu, antipyretic-analgesic, anti-infection, anti-fungal, endocrine, anti-allergy, antibacterial and antiviral, respiratory system, digestive system, and gynecological indications, as well as nutritional supplements. It also provides maternal and infant health products; protective and medical masks; and medical devices, including medical protective equipment. In addition, the company engages in investment, property, planting, internet sales, and leasing activities. It markets its products through pharmaceutical distribution agents, sales terminals, and a marketing network. The company was formerly known as HaiNan Honz Pharmaceutical Co.,Ltd. and changed its name to Honz Pharmaceutical Co., Ltd. in November 2016. Honz Pharmaceutical Co., Ltd. was founded in 1993 and is headquartered in Haikou, China.
Visit company website
5 years, 5 months ago
Honz Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 11.7% below its 200 day moving average.
From a valuation standpoint, the stock is 69.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.9.
Honz Pharmaceutical Co., Ltd's total revenue sank by 8.3% to $221M since the same quarter in the previous year.
Its net income has dropped by 12.9% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 47.7% to $-61M since the same quarter in the previous year.
Based on the above factors, Honz Pharmaceutical Co., Ltd gets an overall score of 2/5.